CRSP Tx (JP Morgan).pdf

1、CRISPR THERAPEUTICS CONFIDENTIAL1 2025 CRISPR Therapeutics|143rd Annual J.P.Morgan Healthcare ConferenceJanuary 14,2025CRISPR THERAPEUTICS CONFIDENTIAL2 2025 CRISPR Therapeutics|2Forward-Looking StatementsThis presentation and related materials may contain statements regarding matters that are not h

2、istorical facts are“forward-looking statements”within the meaning of the Private Securities Litigation Reform Act of 1995.Because such statements are subject to risks and uncertainties,actual results may differ materially from those expressed or implied by such forward-looking statements.Such statem

3、ents include,but are not limited to,statements regarding any or all of the following:(i)CRISPR Therapeutics preclinical studies,clinical trials and pipeline products and programs,including,without limitation,manufacturing capabilities,status of such studies and trials,potential expansion into new in

4、dications and expectations regarding data,safety and efficacy generally;(ii)CRISPR Therapeutics strategy,goals,anticipated financial performance and the sufficiency of its cash resources;(iii)regulatory submissions and authorizations,including timelines for and expectations regarding additional regu

5、latory agency decisions;(iv)the expected benefits of CRISPR Therapeutics collaborations;and(v)the therapeutic value,development,and commercial potential of CRISPR/Cas9 gene editing technologies and therapies,including as compared to other therapies.Risks that contribute to the uncertain nature of th

6、e forward-looking statements include,without limitation,the risks and uncertainties discussed under the heading“Risk Factors”in CRISPR Therapeutics most recent annual report on Form 10-K and in any other subsequent filings made by CRISPR Therapeutics with the U.S.Securities and Exchange Commission.E